Menu

 

 

MORE EXPERTS. MORE INSIGHTS.

Created in partnership with dermatology experts for dermatology experts, PeerspectivesInPsoriasis™ is your one-stop, peer-to-peer resource on BIMZELX®. Check back often for the latest updates, detailed information, and valuable insights from leading experts.

HEAR FROM PSO PEERS

PASI 100 CONSISTENTLY DEMONSTRATED ACROSS HEAD-TO-HEAD CLINICAL TRIALS2-4

Results like this make dermatologists like us stand up and take notice.
-Dr. Bruce Strober

Watch how BIMZELX is reaching higher in psoriasis treatment by targeting COMPLETE CLEARANCE (PASI 100) in head-to-head clinical trials against COSENTYX® (secukinumab), HUMIRA® (adalimumab), and STELARA® (ustekinumab). Then explore the data demonstrating why patients can expect RAPID results and MAINTAIN longer-term clearance with BIMZELX.2-6

TreatmentResponse

Treatment Response Time

Learn how you can give many of your patients the opportunity to achieve skin clearance that can last.

Watch video

HeadToHead

Head-to-Head

Hear how BIMZELX performed in clinical trials against three of the most prescribed biologics.

Watch video

UCB Dermatology|Medical Affairs

Complete Clearance

Find out how BIMZELX can help many patients achieve PASI 100.

Watch video

peerspectives_moa_screenshot

THE BIMZELX DIFFERENCE IS IN THE MOA*

BIMZELX is the first and only approved biologic to inhibit IL-17A and IL-17F.1 Watch the MOA narrative and find out what makes BIMZELX different from other biologics.

*The clinical relevance of the mechanism of action is unknown.

Across different patient populations with different levels of inflammatory skin disease, the amazing thing was the consistency we saw with BIMZELX‑highlighting that IL-17A and IL-17F are really at the heart of this skin disorder.

-Dr. Stevan Shaw

TargetingIL17A

Targeting IL-17A and IL-17F

Discover the significance of IL-17F in psoriasis pathogenesis.

Watch video

Video link. The BIMZELX® logo and the words, “The journey to discovery from the “grandfather” of" are onscreen.

BIMZELX: The Discovery

Learn the story behind BIMZELX from Dr. Stevan Shaw, VP, Head of Immunology Research for UCB.

Watch video

A CONSISTENT SAFETY PROFILE WITH 4 YEARS OF DATA6

The chronic nature of psoriasis requires persistent management, making long-term safety assessment of treatment a cornerstone for clinical decision-making. BIMZELX demonstrated a consistent safety profile over 4 years with low incidences of adverse events across the pooled analysis of short-term and long-term safety data.6

Robust Safety Data Across 5 Phase 3/3b Clinical Trials6

Download PDF

  SHORT TERM
(PHASE 3)*
Weeks 0-16
% (n)		 LONGER TERM
(PHASE 3/3B)†
Year 4
EAIR/100 PY (95% CI)
  BIMZELX 320 MG (n=989) PLACEBO (n=169) BIMZELX ALL DOSES (n=2,186)

Candida infections

9.1% (90)

0%

10.4 (9.5, 11.3)
Oral candidiasis

7.6% (75)

0%

8.9 (8.1, 9.7)
Injection site reactions

2.7% (27)

1.2% (2)

1.7 (1.4, 2.0)
ALT or AST elevations

 

 

 
>3x ULN

 

1.3% (13)

1.2% (2)

1.9 (1.6, 2.3)
>5x ULN‡

0.3% (3)

0%

0.5 (0.4, 0.7)

Malignancies (inc. NMSC)

0.4% (4)

0.6% (1)

0.9 (0.6, 1.1)

Serious infections

0.3% (3)

0%

1.3 (1.0, 1.6)

Adjudicated MACE

0.1% (1)

0%

0.6 (0.4, 0.8)

Adjudicated inflammatory bowel disease§

0.1% (1)

0%

0.2 (0.1, 0.3)

Adjudicated suicidal ideation and behavior

0%

0%

0.1 (0.1, 0.2)

Serious hypersensitivity reactionsll

0%

0%

0.1 (0.0, 0.2)
  * Pooled short-term data from Weeks 0-16 of 3 Phase 3 trials (BE SURE, BE VIVID, and BE READY).6
† Longer-term data from 5 Phase 3/3b trials (Phase 3: BE SURE, BE VIVID, BE READY and their OLE BE BRIGHT; Phase 3b: BE RADIANT). BE RADIANT ran for 3 years; therefore, the total pooled exposure only includes BE RADIANT data to Year 3 (cut-off May 6, 2022) in addition to BE BRIGHT data to Year 4 (cut-off Nov. 14, 2022).6
‡ Patients with elevations >5x ULN were a subset of patients with elevations >3x ULN. 
§ Includes any TEAE adjudicated as definite or probable IBD.6 Long-term data included in the BIMZELX Prescribing Information includes seven cases of new onset IBD (including ulcerative colitis, Crohn’s disease, and IBD-undetermined) in subjects exposed to BIMZELX (0.12 per 100 PY).1
II No anaphylactic reactions associated with BIMZELX were reported.6
ALT=alanine aminotransferase. AST=aspartate aminotransferase. CI=confidence interval. EAIR=exposure-adjusted incidence rate. IBD=inflammatory bowel disease. MACE=major adverse cardiovascular events. NMSC=non-melanoma skin cancer. PY=patient-year. ULN=upper limit of normal.

Investigator ExperienceS

Hear as two investigators share their clinical experiences with BIMZELX in the Phase 3 clinical trials.

Dr_Weisman_Interview_v9e

Investigator Experience–Jamie Weisman, MD

Clinical trial investigator Jamie Weisman, MD, of Atlanta Medical Dermatology Specialists, Inc., discusses her experience with BIMZELX.

Watch video

TheDiscovery

Investigator Experience–Jeffrey Weinberg, MD

Clinical trial investigator Jeffrey Weinberg, MD, of Infinity Dermatology NYC and Mt. Sinai, discusses his experience with BIMZELX.

Watch video

References

1. BIMZELX [prescribing information]. Smyrna, GA: UCB, Inc. 2. Reich K, et al. N Engl J Med. 2021;385(2):142-152. 3. Reich K, et al. Lancet. 2021;397(10273):487-498. 4. Warren RB, et al. N Engl J Med. 2021;385(2):130-141. 5. Gordon KB, et al. Lancet. 2021;397(10273):475-486. 6. Data on file. UCB, Inc., Smyrna, GA.

08/2024 US-BK-2400881

arrow

EXPLORE RAPID, COMPLETE, AND MAINTAINED CLEARANCE FROM THE VERY FIRST DOSE1-5*

View Efficacy

*From the very first dose as measured at Week 4;
results were not immediate.

WANT MORE INFORMATION ABOUT BIMZELX?

Get updates and contact a sales representative

INDICATIONS

BIMZELX is indicated for the treatment of adult patients with active psoriatic arthritis, active non-radiographic axial spondyloarthritis with objective signs of inflammation, active ankylosing spondylitis, and moderate-to-severe plaque psoriasis patients who are candidates for systemic therapy or phototherapy

IMPORTANT SAFETY INFORMATION

Suicidal Ideation and Behavior

BIMZELX® (bimekizumab-bkzx) may increase the risk of suicidal ideation and behavior (SI/B). A causal association between treatment with BIMZELX and increased risk of SI/B has not been established. Prescribers should weigh the potential risks and benefits before using BIMZELX in patients with a history of severe depression or SI/B. Advise monitoring for the emergence or worsening of depression, suicidal ideation, or other mood changes. If such changes occur, advise to promptly seek medical attention, refer to a mental health professional as appropriate, and re-evaluate the risks and benefits of continuing treatment.

Infections

BIMZELX may increase the risk of infections. Do not initiate treatment with BIMZELX in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing BIMZELX. Instruct patients to seek medical advice if signs or symptoms suggestive of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer BIMZELX until the infection resolves.

Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with BIMZELX. Avoid the use of BIMZELX in patients with active TB infection. Initiate treatment of latent TB prior to administering BIMZELX. Consider anti-TB therapy prior to initiation of BIMZELX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Closely monitor patients for signs and symptoms of active TB during and after treatment.

Liver Biochemical Abnormalities

Elevated serum transaminases were reported in clinical trials with BIMZELX. Test liver enzymes, alkaline phosphatase, and bilirubin at baseline, periodically during treatment with BIMZELX, and according to routine patient management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt BIMZELX until a diagnosis of liver injury is excluded. Permanently discontinue use of BIMZELX in patients with causally associated combined elevations of transaminases and bilirubin. Avoid use of BIMZELX in patients with acute liver disease or cirrhosis.

Inflammatory Bowel Disease

Cases of inflammatory bowel disease (IBD) have been reported in patients treated with IL-17 inhibitors, including BIMZELX. Avoid use of BIMZELX in patients with active IBD. During BIMZELX treatment, monitor patients for signs and symptoms of IBD and discontinue treatment if new onset or worsening of signs and symptoms occurs.

Immunizations

Prior to initiating therapy with BIMZELX, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid the use of live vaccines in patients treated with BIMZELX.

MOST COMMON ADVERSE REACTIONS

Most common (≥1%) adverse reactions in plaque psoriasis include upper respiratory tract infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, Herpes Simplex infections, acne, folliculitis, other candida infections, and fatigue.

Most common (≥2%) adverse reactions in psoriatic arthritis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, and urinary tract infections.

Most common (≥2%) adverse reactions in non-radiographic axial spondyloarthritis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, cough, fatigue, musculoskeletal pain, myalgia, tonsillitis, transaminase increase, and urinary tract infections.

Most common (≥2%) adverse reactions in ankylosing spondylitis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, injection site pain, rash, and vulvovaginal mycotic infections.

Please see the full Prescribing Information.

Most common (≥2%) adverse reactions in PsA, nr-axSpA, and AS include upper respiratory tract infections, oral candidiasis, headache, diarrhea, and urinary tract infections. Other most common (≥2%) adverse reactions specific to each indication include: urinary tract infections (PsA); cough, fatigue, musculoskeletal pain, myalgia, tonsillitis, transaminase increase, and urinary tract infections (nr-axSpA); injection site pain, rash, and vulvovaginal mycotic infections (AS).

References:

1. BIMZELX® [prescribing information]. Smyrna, GA: UCB, Inc. 2. Gordon KB, et al. Lancet. 2021;397(10273):475-486. 3. Reich K, et al. N Engl J Med. 2021;385(2):142-152. 4. Iznardo H, et al. Ther Adv Chronic Dis. 2021; 12:20406223211037846. 5. Vidal S, et al. Int J Mol Sci. 2021;22(13):6740.